Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo

被引:0
|
作者
Kayano, Taishi [1 ]
Nishiura, Hiroshi [1 ]
机构
[1] Kyoto Univ, Sch Publ Hlth, Yoshida Konoe Cho,Sakyo Ku, Kyoto 6068501, Japan
关键词
Immunization; COVID-19; Direct effect; Indirect effect; Population-level impact; IMPACT;
D O I
10.1186/s12879-023-08748-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundMany countries, including high-income nations, struggled to control epidemic waves caused by the Omicron variant (B.1.1.529), which had an antigenically distinct evolution. Evaluating the direct and indirect effects of vaccination during the Omicron waves is essential to assess virus control policies. The present study assessed the population impacts of a vaccination program during the sixth wave caused by BA.1 and BA.2 from January to May 2022, in Tokyo.MethodsWe analyzed the primary series and booster vaccination coverages and the confirmed cases stratified by vaccination history. We estimated the number of COVID-19 cases that were directly and indirectly prevented by vaccination. To estimate the direct impact, we used a statistical model that compared risks between unvaccinated and vaccinated individuals. A transmission model employing the renewal process was devised to quantify the total effect, given as the sum of the direct and indirect effects.ResultsAssuming that the reporting coverage of cases was 25%, mass vaccination programs, including primary and booster immunizations, directly averted 640,000 COVID-19 cases (95% confidence interval: 624-655). Furthermore, these programs directly and indirectly prevented 8.5 million infections (95% confidence interval: 8.4-8.6). Hypothetical scenarios indicated that we could have expected a 19% or 7% relative reduction in the number of infections, respectively, compared with the observed number of infections, if the booster coverage had been equivalent to that of the second dose or if coverage among people aged 10-49 years had been 10% higher. If the third dose coverage was smaller and comparable to that of the fourth dose, the total number of infections would have increased by 52% compared with the observed number of infections.ConclusionsThe population benefit of vaccination via direct and indirect effects was substantial, with an estimated 65% reduction in the number of SARS-CoV-2 infections compared with counterfactual (without vaccination) in Tokyo during the sixth wave caused by BA.1 and BA.2.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo
    Taishi Kayano
    Hiroshi Nishiura
    [J]. BMC Infectious Diseases, 23
  • [2] A comprehensive review on Covid-19 Omicron (B.1.1.529) variant
    Manjunath, R.
    Gaonkar, Santosh L.
    Saleh, Ebraheem Abdu Musad
    Husain, Kakul
    [J]. SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2022, 29 (09)
  • [3] Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
    Andrews, N.
    Stowe, J.
    Kirsebom, F.
    Toffa, S.
    Rickeard, T.
    Gallagher, E.
    Gower, C.
    Kall, M.
    Groves, N.
    O'connell, A-M
    Simons, D.
    Blomquist, P. B.
    Zaidi, A.
    Nash, S.
    Aziz, N. Iwani Binti Abdul
    Thelwall, S.
    Dabrera, G.
    Myers, R.
    Amirthalingam, G.
    Gharbia, S.
    Barrett, J. C.
    Elson, R.
    Ladhani, S. N.
    Ferguson, N.
    Zambon, M.
    Campbell, C. N. J.
    Brown, K.
    Hopkins, S.
    Chand, M.
    Ramsay, M.
    Bernal, J. Lopez
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (16): : 1532 - 1546
  • [4] COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a at the end of the tunnel?
    Mattiuzzi, Camilla
    Henry, Brandon M.
    Lippi, Giuseppe
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 118 : 167 - 168
  • [5] DRUG DESIGN OF MEDICINAL PLANTS AS A TREATMENT OF OMICRON VARIANT (COVID-19 VARIANT B.1.1.529)
    Mollaamin, Fatemeh
    Shahriari, Sara
    Monajjemi, Majid
    [J]. JOURNAL OF THE CHILEAN CHEMICAL SOCIETY, 2022, 67 (03): : 5562 - 5570
  • [6] SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
    Afshar, Zeinab Mohseni
    Pirzaman, Ali Tavakoli
    Karim, Bardia
    Anaraki, Shiva Rahimipour
    Hosseinzadeh, Rezvan
    Pireivatlou, Elaheh Sanjari
    Babazadeh, Arefeh
    Hosseinzadeh, Dariush
    Miri, Seyed Rouhollah
    Sio, Terence T.
    Sullman, Mark J. M.
    Barary, Mohammad
    Ebrahimpour, Soheil
    [J]. DIAGNOSTICS, 2023, 13 (03)
  • [7] Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
    Gruene, Barbara
    Gruene, Jakob
    Kossow, Annelene
    Joisten, Christine
    [J]. VACCINES, 2022, 10 (07)
  • [8] Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant
    Lippi, Giuseppe
    Mattiuzzi, Camilla
    Henry, Brandon M.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) : 1799 - 1802
  • [9] Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant
    Hu, Songhua
    Xiong, Chenfeng
    Zhao, Yingrui
    Yuan, Xin
    Wang, Xuqiu
    [J]. VACCINE, 2023, 41 (35) : 5097 - 5112
  • [10] Epidemic waves caused by SARS-CoV-2 omicron (B.1.1.529) and pessimistic forecasts of the COVID-19 pandemic duration
    Nesteruk, Igor
    [J]. MEDCOMM, 2022, 3 (01):